108.91
전일 마감가:
$110.02
열려 있는:
$109.15
하루 거래량:
867.91K
Relative Volume:
0.81
시가총액:
$26.18B
수익:
$2.97B
순이익/손실:
$-812.83M
주가수익비율:
-32.07
EPS:
-3.3962
순현금흐름:
$-1.24B
1주 성능:
-1.88%
1개월 성능:
+2.23%
6개월 성능:
-7.11%
1년 성능:
+27.44%
바이오앤테크 Stock (BNTX) Company Profile
BNTX을(를) 다른 주식과 비교
주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
---|---|---|---|---|---|---|
![]()
BNTX
Biontech Se Adr
|
108.91 | 26.68B | 2.97B | -812.83M | -1.24B | -3.3962 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
458.49 | 121.30B | 11.10B | -988.90M | -1.26B | -3.92 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
545.53 | 61.60B | 14.09B | 4.50B | 2.96B | 39.28 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
320.52 | 41.17B | 2.35B | -269.70M | -75.39M | -2.09 |
![]()
ARGX
Argen X Se Adr
|
566.14 | 34.35B | 2.58B | 1.06B | -1.28B | 16.33 |
![]()
ONC
Beone Medicines Ltd Adr
|
291.93 | 27.29B | 3.81B | -644.79M | -669.77M | -6.24 |
바이오앤테크 Stock (BNTX) Upgrades & Downgrades
날짜 | 액션 | 분석자 | 등급 변경 |
---|---|---|---|
2025-06-05 | 재확인 | H.C. Wainwright | Buy |
2025-05-29 | 개시 | Goldman | Neutral |
2025-03-13 | 개시 | Citigroup | Buy |
2025-01-10 | 개시 | Truist | Buy |
2024-12-11 | 개시 | Wells Fargo | Overweight |
2024-12-02 | 재확인 | BMO Capital Markets | Outperform |
2024-11-19 | 개시 | Berenberg | Buy |
2024-11-19 | 업그레이드 | Evercore ISI | In-line → Outperform |
2024-11-08 | 업그레이드 | Goldman | Neutral → Buy |
2024-09-24 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
2024-09-17 | 업그레이드 | Jefferies | Hold → Buy |
2024-09-16 | 업그레이드 | JP Morgan | Underweight → Neutral |
2024-08-07 | 업그레이드 | Deutsche Bank | Hold → Buy |
2024-08-02 | 업그레이드 | HSBC Securities | Hold → Buy |
2024-05-14 | 개시 | Evercore ISI | In-line |
2024-02-23 | 개시 | BMO Capital Markets | Outperform |
2024-01-05 | 개시 | Oppenheimer | Perform |
2023-12-01 | 다운그레이드 | JP Morgan | Neutral → Underweight |
2023-10-16 | 다운그레이드 | HSBC Securities | Buy → Hold |
2023-07-14 | 개시 | HSBC Securities | Buy |
2023-05-17 | 업그레이드 | Redburn | Neutral → Buy |
2022-12-15 | 업그레이드 | BofA Securities | Neutral → Buy |
2022-08-17 | 개시 | Cowen | Market Perform |
2022-07-13 | 업그레이드 | SVB Leerink | Mkt Perform → Outperform |
2022-07-06 | 재개 | Canaccord Genuity | Buy |
2022-02-01 | 업그레이드 | Redburn | Sell → Neutral |
2021-12-16 | 개시 | Morgan Stanley | Equal-Weight |
2021-11-10 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
2021-10-22 | 개시 | Deutsche Bank | Hold |
2021-10-07 | 개시 | Jefferies | Hold |
2021-08-11 | 업그레이드 | Bryan Garnier | Neutral → Buy |
2021-07-19 | 재개 | Wolfe Research | Outperform |
2021-06-16 | 다운그레이드 | Redburn | Neutral → Sell |
2021-05-18 | 개시 | Goldman | Neutral |
2021-05-11 | 다운그레이드 | Bryan Garnier | Buy → Neutral |
2020-12-01 | 다운그레이드 | BofA Securities | Buy → Neutral |
2020-08-03 | 재개 | Berenberg | Buy |
2020-07-21 | 업그레이드 | BofA Securities | Neutral → Buy |
2020-06-30 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
2020-05-19 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
2020-04-28 | 다운그레이드 | BofA/Merrill | Buy → Neutral |
2020-03-18 | 다운그레이드 | JP Morgan | Overweight → Neutral |
2020-03-09 | 개시 | H.C. Wainwright | Neutral |
2020-01-24 | 다운그레이드 | SVB Leerink | Outperform → Mkt Perform |
2020-01-22 | 다운그레이드 | UBS | Buy → Neutral |
2019-11-05 | 개시 | Wolfe Research | Outperform |
2019-11-04 | 개시 | Berenberg | Buy |
2019-11-04 | 개시 | BofA/Merrill | Buy |
2019-11-04 | 개시 | Canaccord Genuity | Buy |
2019-11-04 | 개시 | JP Morgan | Overweight |
2019-11-04 | 개시 | SVB Leerink | Outperform |
2019-11-04 | 개시 | UBS | Buy |
모두보기
바이오앤테크 주식(BNTX)의 최신 뉴스
BioNTech’s BNT327 Clinical Trial: A New Hope for Small-Cell Lung Cancer? - MSN
Pfizer and BioNTech’s New Shingles Vaccine Study: What Investors Need to Know - TipRanks
BioNTech’s BNT327 Trial: A Potential Game-Changer in Lung Cancer Treatment? - TipRanks
BioNTech’s Promising Lung Cancer Trial: A Potential Game-Changer for NSCLC Treatment - TipRanks
BioNTech Announces Ryan Richardson to Step Down from the Management Board17.07.25News - Ariva
OneDigital Investment Advisors LLC Makes New Investment in BioNTech SE Sponsored ADR (NASDAQ:BNTX) - Defense World
BioNTech’s Promising Phase III Trial for Recurrent Endometrial Cancer - TipRanks
BioNTech’s Latest Clinical Trial: A New Hope for Lung Cancer Treatment? - TipRanks
BioNTech’s Phase II Trial: A Potential Game-Changer in Colorectal Cancer Treatment - TipRanks
Regeneron and BioNTech’s Promising Lung Cancer Trial: What Investors Need to Know - TipRanks
BioNTech SE Receives Buy Rating from BMO Capital with $143 Price Target - AInvest
Genmab and BioNTech’s GEN1056 Study: A New Hope for Advanced Solid Tumors - TipRanks
Genmab and BioNTech’s Immunoradiotherapy Study: A Potential Game-Changer in Cancer Treatment - TipRanks
Genmab and BioNTech’s Promising Cancer Trial: A Potential Game-Changer? - TipRanks
Genmab and BioNTech’s GEN1042 Study: A New Hope for Cancer Treatment? - TipRanks
BioNTech SE Sponsored ADR (NASDAQ:BNTX) Receives Consensus Recommendation of “Moderate Buy” from Analysts - Defense World
GAMMA Investing LLC Sells 334 Shares of BioNTech SE Sponsored ADR (NASDAQ:BNTX) - Defense World
BioNTech’s Phase III Trial: A Potential Game-Changer in Endometrial Cancer Treatment - TipRanks
Genmab and BioNTech’s Promising Immunoradiotherapy Study for Metastatic Tumors - TipRanks
Genmab and BioNTech’s Pioneering Cancer Trial: A Potential Game-Changer? - TipRanks
Genmab and BioNTech’s GEN1056 Study: A Potential Game-Changer in Oncology - TipRanks
Genmab and BioNTech’s GEN1042 Study: A New Hope in Cancer Treatment - TipRanks
Genmab and BioNTech’s GEN1042 Study: A Potential Game-Changer in Cancer Treatment - TipRanks
BioNTech SE’s BNT317 Study: A New Hope for Advanced Solid Tumors - TipRanks
BioNTech’s BNT151 Study Update: Early Termination and Market Implications - TipRanks
BioNTech ADR Earns Relative Strength Rating Upgrade - MSN
Biontech SE’s BNT317 Study: A New Hope for Advanced Solid Tumors - TipRanks
BioNTech’s Latest Clinical Trial: A New Hope for NSCLC Treatment? - TipRanks
What is HC Wainwright’s Forecast for BioNTech Q3 Earnings? - Defense World
BioNTech ADR Gets Relative Strength Rating Upgrade - Investor's Business Daily
BioNTech’s Promising Phase II Study: A Potential Game-Changer in Cancer Treatment - TipRanks
BioNTech SE’s Promising Study on Pancreatic Cancer Treatment: What Investors Need to Know - TipRanks
BioNTech’s BNT327: A Promising Phase II Trial for Small-Cell Lung Cancer - TipRanks
CureVac Soars 41% in a Month on a $1.25B Buyout Offer From BioNTech - Zacks Investment Research
Equities Analysts Issue Forecasts for BioNTech Q4 Earnings - Defense World
BioNTech (BNTX) – Analysts’ Recent Ratings Changes - Defense World
Private-Public Deal Momentum Grows, Yet Megamergers Stay Elusive - Investing.com
HC Wainwright Estimates BioNTech’s Q4 Earnings (NASDAQ:BNTX) - Defense World
Market Update: Abercrombie & Fitch Co (ANF) Sees Positive Movement, Closing at 75.00 - DWinneX
Gaining Ground: fuboTV Inc (FUBO) Closes Higher at 3.26, Up 2.84 - DWinneX
Market Resilience: Nerdy Inc (NRDY) Finishes Strong at 1.63, Up 2.52 - DWinneX
5 Stocks To Ride The German Market RallyCureVac (NASDAQ:CVAC), BioNTech (NASDAQ:BNTX) - Benzinga
Riding the Waves: A Guide to Investing in ARBE Stock - investchronicle.com
BMY Reports Positive Data On Sotyktu From Arthritis Study - Barchart.com
Erasca Inc (ERAS) Stock: 52-Week Performance Insights and Trading Volume - investchronicle.com
CureVac stock soars about 30% after BioNTech agrees to acquire co By Investing.com - Investing.com South Africa
Vaccine stocks muted as investors assess Kennedy’s overhaul of key panel - The Globe and Mail
Robert Kennedy Jr Axes Entire CDC Vaccine Panel To 'Restore Public Trust' — Pfizer, Moderna, Other Biotech Stocks Drop In After-Hours Trading - Benzinga
BMY Collaborates for Oncology Drug: Will This Boost Its Portfolio? - The Globe and Mail
Is BioNTech Stock A Buy On Major $11 Billion Cancer-Drug Deal? - Barchart.com
Bristol Myers Collaborates With BNTX for Oncology Candidate - sharewise
바이오앤테크 (BNTX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
자본화:
|
볼륨(24시간):